CTOs on the Move

Kaken Pharmaceuticals

www.kaken.com

 
Kaken Pharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $500M-1 Billion
  • www.kaken.com
  • 245 Park Ave New York
    New York, NY USA 10167
  • Phone: 212.372.8910

Executives

Name Title Contact Details

Similar Companies

Adrian Elwell at Au Top

Adrian Elwell at Au Top is a Danville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

3-V Biosciences

3-V Biosciences, Inc. is discovering and developing therapeutics that modulate key pathways in oncology and infectious diseases. In oncology, the company`s lead candidate is a first-in-class, oral fatty acid synthase (FASN) inhibitor in Phase 1 clinical development that has been shown to block tumor cell signaling pathways and induce tumor cell apoptosis. 3-V`s antiviral therapeutics have demonstrated the ability to block host-pathogen interactions, resulting in robust and broad-spectrum in vitro and in vivo antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance. The 3-V team applies an integrated approach, leveraging internal expertise in biology, medicinal chemistry, drug discovery and development to drive programs forward. The company is located in Menlo Park, California.

Cleave Biosciences

Cleave Biosciences is a biopharmaceutical company pioneering the development of novel protein homeostasis inhibitors for the treatment of cancer.

Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets.

Aspira Women`s Health

Aspira Women`s Health Inc. (formerly known as Vermillion, Inc. Nasdaq: VRML) is transforming women`s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1®plus combines our FDA-cleared products OVA1® and OVERA® to detect the risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiXSM testing offers both targeted and a more comprehensive genetic testing options with a gynecologic focus. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment.